Janus Henderson High-Yield Fund Q4 2025 Commentary

Janus Henderson High-Yield Fund returned 1.49% and the Bloomberg U.S. Corporate High Yield Bond Index returned 1.31%. Read ...

Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028

Full-year results and business updateTransgene Continues Progressto Reshape Early-Stage Cancer Treatmentthrough Individualized Neoantigen ...